Leukemia, Mast-Cell: Clinical Trials

10 trials for Leukemia, Mast-Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 terminated, 1 withdrawn. 10 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 7, Terminated 2, Withdrawn 1
Phase 25Completed 3, Terminated 1, Withdrawn 1

Follow Leukemia, Mast-Cell: new trials by email Literature Review of Leukemia, Mast-Cell trials Research Report on Leukemia, Mast-Cell

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
BLU-263, Azacitidine - Advanced Systemic Mastocytosis
Phase 1TerminatedBlueprint Medicines Corporation92023-09-252025-04-10
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Phase 1 / Phase 2TerminatedGT Biopharma, Inc.122020-01-012022-11-10
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Avapritinib - Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
Phase 1CompletedBlueprint Medicines Corporation862016-03-102023-03-17
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
Phase 1CompletedDeciphera Pharmaceuticals, LLC2822015-11-012023-12-13
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
Phase 1CompletedNational Cancer Institute (NCI)452011-01-012014-04-29
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Phase 1CompletedNational Cancer Institute (NCI)422009-08-012014-03-17
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Phase 1 / Phase 2CompletedAsan Medical Center472009-01-012013-02-20
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
PS-341, Doxil, Velcade - Breast Cancer, Leukemia
Phase 1 / Phase 2CompletedUNC Lineberger Comprehensive Cancer Center1072001-05-012012-05-18
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center212000-05-012020-01-21
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole - Chronic Myeloproliferative Disorders, Infection
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2013-02-15

Narrower conditions

Leukemia, Myeloid, Acute (7)  ·  Burkitt Lymphoma (6)  ·  Intraocular Lymphoma (6)  ·  Leukemia, Hairy Cell (6)  ·  Leukemia, Large Granular Lymphocytic (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (6)  ·  Leukemia, Myelomonocytic, Chronic (6)  ·  Lymphoma, B-Cell, Marginal Zone (6)  ·  Lymphoma, Extranodal NK-T-Cell (6)  ·  Lymphoma, Follicular (6)  ·  Lymphoma, Large B-Cell, Diffuse (6)  ·  Lymphoma, Large-Cell, Anaplastic (6)  ·  Lymphoma, Mantle-Cell (6)  ·  Mycosis Fungoides (6)

Broader conditions

Hematologic Diseases (10)  ·  Hemic and Lymphatic Diseases (10)  ·  Immune System Diseases (10)  ·  Leukemia, Myeloid (10)  ·  Mastocytosis (10)  ·  Neoplasms (10)  ·  Neoplasms by Histologic Type (10)  ·  Mast Cell Activation Disorders (9)  ·  Bone Marrow Diseases (8)  ·  Disease Attributes (7)  ·  Leukemia (7)  ·  Neoplasms by Site (7)  ·  Pathologic Processes (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Blood Protein Disorders (6)

Interventions

Azacitidine (1)  ·  Bortezomib (1)  ·  Cyclosporine (1)  ·  Edetic Acid (1)  ·  Ethanol (1)  ·  MK 2206 (1)  ·  Mycophenolic Acid (1)  ·  Pentetic Acid (1)  ·  Peripheral Blood Stem Cell Transplantation (1)  ·  Saline Solution (1)  ·  Saline Solution, Hypertonic (1)  ·  Sodium Chloride (1)  ·  Sulfamethoxazole (1)  ·  Sunitinib (1)  ·  Trimethoprim (1)

Sponsors

Blueprint Medicines Corporation (2)  ·  National Cancer Institute (NCI) (2)  ·  Asan Medical Center (1)  ·  Deciphera Pharmaceuticals, LLC (1)  ·  Fred Hutchinson Cancer Center (1)  ·  GT Biopharma, Inc. (1)  ·  M.D. Anderson Cancer Center (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)

Countries

United States (8)  ·  Canada (2)  ·  Germany (2)  ·  Italy (2)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  France (1)  ·  Norway (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

David Maloney (1)  ·  Elizabeth C. Dees, MD (1)  ·  John Deeken (1)  ·  Jorge Cortes, MD (1)  ·  Kyoo H. Lee, MD (1)  ·  Mark B Juckett, MD (1)  ·  Maryam Fouladi (1)  ·  Patrick Chaftari, MD (1)  ·  Robert Z. Orlowski, MD, PhD (1)

Results publications

PMID 18327587, PMID 22259028, PMID 24474568, PMID 32499241, PMID 32804590, PMID 34873347, PMID 35640224, PMID 35790816

NIH funding

2015 (1), P01CA078902 (1), P30CA015704 (1), U01CA097452 (1), U01CA121947 (1)